Joseph P. Slattery
Joseph P. Slattery's purchase track record
How the stock did after each of Joseph P. Slattery's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/24/2025 | IMA | $96K | -5.0% | +2.6% | +6.2% |
| 8/15/2024 | CVRX | $24K | +76.4% | +80.9% | +10.3% |
| 8/6/2024 | CVRX | $47K | +70.4% | +79.6% | +15.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
ImageneBio Reports Inducement Grants Under Nasdaq Rule. ImageneBio has disclosed new inducement grants in compliance with Nasdaq Listing Rule 5635(c)(4). This filing is a standard corporate disclosure regarding compensation and does not report new clinical data or financial results. The stock is currently trading within its 52-week range, with an average analyst target of $18.00.
Transaction History
| CVRX | ▲ Buy | Grant | 8,720 | $0 | 6/1/2026 | View on chart |
| IMA | ▲ Buy | Open Market | 16,000 | $96K | 12/24/2025 | View on chart |
| CVRX | ▲ Buy | Open Market | 3,000 | $24K | 8/15/2024 | View on chart |
| CVRX | ▲ Buy | Open Market | 3,000 | $25K | 8/8/2024 | View on chart |
| CVRX | ▲ Buy | Open Market | 2,500 | $23K | 8/6/2024 | View on chart |
| CVRX | ▲ Buy | Option Exercise | 96 | $380 | 12/28/2023 | View on chart |
| CVRX | ▲ Buy | Option Exercise | 174 | $206 | 12/28/2023 | View on chart |
| CVRX | ▲ Buy | Option Exercise | 224 | $53 | 12/28/2023 | View on chart |
| CVRX | ▲ Buy | Option Exercise | 1,456 | $345 | 12/28/2023 | View on chart |
| CVRX | ▲ Buy | Option Exercise | 2,149 | $509 | 1/13/2022 | View on chart |
| CVRX | ▲ Buy | Option Exercise | 3,917 | $928 | 1/13/2022 | View on chart |
| CVRX | ▲ Buy | Option Exercise | 316 | $75 | 1/13/2022 | View on chart |
| CVRX | ▲ Buy | Option Exercise | 316 | $75 | 1/13/2022 | View on chart |
| CVRX | ▲ Buy | Option Exercise | 2,528 | $599 | 1/13/2022 | View on chart |
| CVRX | ▲ Buy | Option Exercise | 189 | $45 | 1/13/2022 | View on chart |
| CVRX | ▲ Buy | Option Exercise | 189 | $45 | 1/13/2022 | View on chart |
| CVRX | ▲ Buy | Option Exercise | 189 | $45 | 1/13/2022 | View on chart |
| CVRX | ▲ Buy | Option Exercise | 189 | $45 | 1/13/2022 | View on chart |
| CVRX | ▲ Buy | Option Exercise | 316 | $75 | 1/13/2022 | View on chart |
| CVRX | ▲ Buy | Option Exercise | 758 | $180 | 1/13/2022 | View on chart |
| CVRX | ▲ Buy | Option Exercise | 584 | $693 | 1/13/2022 | View on chart |
| CVRX | ▲ Buy | Option Exercise | 3,000 | $720 | 11/30/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
CVRx Appoints John Landry as CFO
CVRx announced that John Landry will become chief financial officer, effective Oct. 12, replacing Jared Oasheim. The change follows a routine leadership transition and may bring new financial oversight to the company. The appointment is noted by market watchers but does not alter the current trading range or technical signals. Investors can monitor how the new CFO’s approach aligns with the company’s financial goals.
CVRx Appoints John Landry as CFO. CVRx announced that John Landry will become chief financial officer, effective Oct. 12, replacing Jared Oasheim. The change follows a routine leadership transition and may bring new financial oversight to the company. The appointment is noted by market watchers but does not alter the current trading range or technical signals. Investors can monitor how the new CFO’s approach aligns with the company’s financial goals.